The Angiopoietin Signaling Pathway Is Involved in Inflammatory Processes in Hospitalized COVID-19 Patients.

Area of Science:

• Cardiovascular Medicine
• Immunology
• Virology

Background:

• SARS-CoV-2 infection affects multiple organ systems, notably the cardiovascular system.
• Angiopoietins (Ang1 and Ang2) regulate vascular integrity and angiogenesis.
• Interleukin-6 (IL-6) and angiopoietin-2 (Ang2) pathway activation are implicated in COVID-19-associated vasculopathy.

Purpose of the Study:

• To investigate serum levels of angiopoietins, IL-6, and anti-SARS-CoV-2 IgG in COVID-19 patients.
• To correlate these levels with disease severity and patient outcomes.
• To explore the role of the angiopoietin pathway in COVID-19 pathogenesis.

Main Methods:

• Measurement of serum angiopoietin-1 (Ang1), angiopoietin-2 (Ang2), IL-6, and anti-SARS-CoV-2 IgG titers.
• Comparison of levels between hospitalized COVID-19 patients (across severity) and healthy controls.
• Analysis of longitudinal changes in Ang1 and Ang2 levels in relation to adverse outcomes (death, prolonged hospitalization).

Main Results:

• COVID-19 patients exhibited elevated Ang2 and decreased Ang1 levels compared to controls.
• Patients with adverse outcomes had persistently low Ang1 and high Ang2 levels.
• Patients without adverse outcomes showed transient increases in both Ang1 and Ang2.
• Severe COVID-19 cases showed elevated IL-6 and anti-SARS-CoV-2 spike protein IgG.

Conclusions:

• Dynamic changes in Ang1 and Ang2 levels during COVID-19 clinical course can predict adverse outcomes.
• Angiopoietin signaling plays a significant role in the inflammatory response and vascular complications of COVID-19.
• Ang1 may help mitigate Ang2-driven inflammatory mechanisms in COVID-19.